Actelion Pharmaceuticals Ltd. was established nearly twenty decades ago in 1997 by its co-founder and also the current CEO, cardiologist Jean-Paul Clozel. The other co-founders are Martin Clozel, Walter Fischli, Andre J. Muller, and Thomas Widmann. The company is headquartered at Basel-Country, Switzerland.
Actelion is the first company to have its scientists work in the field of endothelin receptor antagonists. Initially, the company was financed with venture capital provided through Safinnova, Atlas Venture, and HealthCap. The Actelion company established Actelion Endothelin Research Award Programme in 2006 to support other clinical research projects. The company has been successfully spreading its wings since its inception and today it has over 30 affiliates all over the world.